Myloop (Ethinylestradiol, Etonogestrel)

Ethinylestradiol/Etonogestrel, the active ingredient in Myloop, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring for vaginal use. It provides hormonal contraception to prevent pregnancy in women of reproductive age. The device releases a steady dose of hormones over three weeks, after which it is removed and replaced with a new ring.

GNH USA supplies Myloop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality control, proper packaging, and timely delivery to meet global demand.

Myloop, a combined estrogen‑progestogen vaginal ring, is indicated for hormonal contraception and related menstrual management.

- Contraception: Prevents pregnancy in women of childbearing potential. - Menstrual cycle regulation: Promotes more predictable bleeding patterns and reduces irregular spotting. - Management of dysmenorrhea: Decreases menstrual pain associated with ovulation.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Vaginal irritation: itching or discharge at the insertion site. - Spotting or breakthrough bleeding: irregular light bleeding. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Hepatic adenoma or tumor: abnormal liver growth. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypertension: sudden increase in blood pressure. - Vision changes: blurred vision or visual disturbances. - Gallbladder disease: inflammation or stones.

Before prescribing Myloop, clinicians should assess individual risk factors and contraindications. - Contraindicated in pregnancy: Category X, do not use during any stage of pregnancy. - Avoid in smokers over 35 years: increased risk of cardiovascular events. - Screen for history of thromboembolism: contraindicated in patients with prior clotting disorders. - Monitor blood pressure regularly: hormonal therapy may elevate blood pressure. - Assess liver function: caution in patients with active hepatic disease. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Myloop may interact with other medicines that affect hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Antiretroviral protease inhibitors (e.g., ritonavir): may decrease hormone levels. - St. John's Wort: can lower plasma concentrations of the active hormones.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): may increase hormone exposure. - Macrolide antibiotics (e.g., erythromycin): may affect hepatic metabolism. - Selective serotonin reuptake inhibitors (SSRIs): may heighten risk of mood‑related side effects.